Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.semarthrit.2020.05.010 http://scihub22266oqcxt.onion/10.1016/j.semarthrit.2020.05.010 32512263!7245236!32512263     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32512263&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Semin+Arthritis+Rheum 2020 ; 50 (4): 680-686 Nephropedia Template TP {{tp|p=32512263|t=2020. COVID-19 in rheumatic disease patients on immunosuppressive agents |pdf=|usr=}}{{32512263}} gab.com Text COVID-19 in rheumatic disease patients on immunosuppressive agents JO: Semin Arthritis Rheum http://www.kidney.de/pget.php?&tw=1&pmid=32512263 #FOAvip OBJECTIVE: To analyze clinical characteristics and outcome of COVID-19 patients with underlying rheumatic diseases (RD) on immunosuppressive agents. METHOD: A case series of COVID-19 patients with RD on disease modifying anti-rheumatic drugs (DMARDs) were studied by a retrospective chart review. A literature search identified 9 similar studies of single cases and case series, which were also included. RESULTS: There were 4 COVID-19 inpatients with RD from our hospital, and the mean age was 57 +/- 21 years. Two patients had a mild infection, and 2 developed severe COVID-19 related respiratory complications, including 1 patient on secukinumab requiring mechanical ventilation and 1 patient on rituximab developing viral pneumonia requiring supplemental oxygenation. All 4 patients had elevated acute phase reactants, 2 patients had mild COVID-19 with lymphopenia, and 2 patients had severe COVID-19 with normal lymphocyte counts, and high levels of IL-6. None of the patients exhibited an exacerbation of their underlying RD. In the literature, there were 9 studies of COVID-19 involving 197 cases of various inflammatory RD. Most patients were on DMARDs or biologics, of which TNFalpha inhibitors were most frequently used. Two tocilizumab users had a mild infection. Two patients were on rituximab with 1 severe COVID-19 requiring mechanical ventilation. Six patients were on secukinumab with 1 hospitalization. Of the total 201 cases, 12 died, with an estimated mortality of 5.9% CONCLUSION: Patients with RD are susceptible to COVID-19. Various DMARDs or biologics may affect the viral disease course differently. Patients on hydroxychloroquine, TNFalpha antagonists or tocilizumab may have a mild viral illness. Rituximab or secukinumab could worsen the viral disease. Further study is warranted. Twit Text FOAVip COVID-19 in rheumatic disease patients on immunosuppressive agents ????Semin Arthritis Rheum http://www.kidney.de/pget.php?&tw=1&pmid=32512263 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32512263 #FOAvip English Wikipedia <ref>{{Cite pmid|32512263}}</ref> COVID-19 in rheumatic disease patients on immunosuppressive agents #MMPMID32512263 Sharmeen S; Elghawy A; Zarlasht F; Yao Q Semin Arthritis Rheum 2020[Aug]; 50 (4): 680-686 PMID32512263show ga OBJECTIVE: To analyze clinical characteristics and outcome of COVID-19 patients with underlying rheumatic diseases (RD) on immunosuppressive agents. METHOD: A case series of COVID-19 patients with RD on disease modifying anti-rheumatic drugs (DMARDs) were studied by a retrospective chart review. A literature search identified 9 similar studies of single cases and case series, which were also included. RESULTS: There were 4 COVID-19 inpatients with RD from our hospital, and the mean age was 57 +/- 21 years. Two patients had a mild infection, and 2 developed severe COVID-19 related respiratory complications, including 1 patient on secukinumab requiring mechanical ventilation and 1 patient on rituximab developing viral pneumonia requiring supplemental oxygenation. All 4 patients had elevated acute phase reactants, 2 patients had mild COVID-19 with lymphopenia, and 2 patients had severe COVID-19 with normal lymphocyte counts, and high levels of IL-6. None of the patients exhibited an exacerbation of their underlying RD. In the literature, there were 9 studies of COVID-19 involving 197 cases of various inflammatory RD. Most patients were on DMARDs or biologics, of which TNFalpha inhibitors were most frequently used. Two tocilizumab users had a mild infection. Two patients were on rituximab with 1 severe COVID-19 requiring mechanical ventilation. Six patients were on secukinumab with 1 hospitalization. Of the total 201 cases, 12 died, with an estimated mortality of 5.9% CONCLUSION: Patients with RD are susceptible to COVID-19. Various DMARDs or biologics may affect the viral disease course differently. Patients on hydroxychloroquine, TNFalpha antagonists or tocilizumab may have a mild viral illness. Rituximab or secukinumab could worsen the viral disease. Further study is warranted. |*Antirheumatic Agents/classification/therapeutic use[MESH] |*Coronavirus Infections/immunology/mortality/therapy[MESH] |*Pandemics[MESH] |*Pneumonia, Viral/immunology/mortality/therapy[MESH] |*Rheumatic Diseases/drug therapy/epidemiology/immunology[MESH] |Betacoronavirus/isolation & purification[MESH] |Biological Products/*therapeutic use[MESH] |COVID-19[MESH] |Female[MESH] |Humans[MESH] |Immunosuppressive Agents/therapeutic use[MESH] |Lymphocyte Count/methods/statistics & numerical data[MESH] |Male[MESH] |Middle Aged[MESH] |Mortality[MESH] |Outcome and Process Assessment, Health Care[MESH] |Respiration, Artificial/methods/statistics & numerical data[MESH] |Retrospective Studies[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH]COVID-19 in rheumatic disease patients on immunosuppressive agents (epmc).pdf DeepDyve Pubget Overpricing